Literature DB >> 29500765

Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma.

Kevin L Anderson1, Mohamed A Adam2, Samantha M Thomas3,4, Linda Youngwirth2, Michael T Stang1,2,4, Randall P Scheri5,6,7, Sanziana A Roman1,2,4, Julie A Sosa1,2,4,8.   

Abstract

PURPOSE: Adrenocortical carcinoma (ACC) is a rare, aggressive cancer; complete surgical resection offers the best chance for long-term survival. The impact of surgical margin status on survival is poorly understood. Our objective was to determine the association of margin status with survival.
METHODS: Patients with ACC were identified from the National Cancer Data Base, 1998-2012, and stratified based on surgical margin status (negative vs. microscopically positive [+] vs. macroscopically [+]). Univariate/multivariate regression/survival analyses were utilized to determine factors associated with margin status and overall survival (OS).
RESULTS: A total of 1553 patients underwent surgery at 589 institutions: 86% had negative, 12% microscopically (+), and 2% macroscopically (+) margins. Those with microscopically (+) and macroscopically (+) margins more often received adjuvant chemotherapy (39.4% macroscopically (+) vs. 38.5% microscopically (+) vs. 25.2% negative margins, p < 0.001). For unadjusted analysis, there was a significant difference in OS between the groups (log-rank p < 0.001), with median survival times of 58 months (95% confidence interval [CI] 49-66) for those with negative margins, 22 months (95% CI 18-34) microscopically (+), and 14 months (95% CI 6-27) macroscopically (+) margins. After adjustment, both microscopically (+) (HR 1.76, p < 0.001) and macroscopically (+) (HR 2.10, p = 0.0019) margin status were associated with compromised survival.
CONCLUSIONS: Having micro- or macroscopically (+) margin status after ACC resection is associated with dose-dependent compromised survival. These results underscore the importance of achieving negative surgical margins for optimizing long-term patient outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 29500765     DOI: 10.1245/s10434-018-6398-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.

Authors:  Jiayu Liang; Zhihong Liu; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Xin Wei; Yiping Lu; Yuchun Zhu
Journal:  Endocrine       Date:  2019-11-30       Impact factor: 3.633

2.  Stage and disease-free interval help select patients for surgical management of locally recurrent and metastatic adrenocortical carcinoma.

Authors:  Winifred Lo; Reed I Ayabe; Christine M Kariya; Meghan L Good; Seth M Steinberg; Jeremy L Davis; Robert T Ripley; Jonathan M Hernandez
Journal:  J Surg Oncol       Date:  2019-12-06       Impact factor: 2.885

Review 3.  Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions.

Authors:  Sara Bedrose; Marilyne Daher; Lina Altameemi; Mouhammed Amir Habra
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.